Pioneer of Rational Drug Design ... Gertrude Elion
On February 21, 1999, Gertrude Elion, who won the Nobel Prize for Physiology of Medicine, died suddenly at age 81. She was born in 1918 in New York. While she was in her teens, her grandfather and mother died of cancer. Their deaths were to shape her lifelong interest in cancer treatment.
After she received a master's degree in chemistry from New York University in 1941, she tried to get a job as a scientist but women were not generally accepted as scientists at the time. Instead, she taught nurses. And then she tested pickles and berries for a food company.
Elion got her big break because there was a manpower shortage in the pharmaceutical industry during World War II. She was hired at Burroughs Wellcome as an assistant to Dr. George Hitchings in 1944.
Together with Dr. Hitchings, she began comparing normal human cells with cancer cells and pathogenic (disease-causing) organisms. Their aim was to discover differences in how nucleic acids (the building blocks of DNA and RNA) are metabolized in these diverse cells.
Elion and Hitchings exploited those differences in nucleic acid metabolism to create highly targeted drugs that selectively blocked the growth and reproduction of certain cancer cells and pathogenic organisms. This approach to drug development was entirely new. Elion and Hitchings did not just sit and screen randomly chosen molecules, as was commonplace at the time. They used their knowledge of nucleic acids to design new drugs.
The revolutionary approach of Elion and Hitchings led them to
discover new drugs at a remarkable rate. Elion and Hitchings
identified two important anticancer drugs, thioguanine and 6-
mercaptopurine. Then pyrimethamine, a drug used successfully in the
management of malaria. Next came an antibacterial drug in common use
for urine infections, trimethoprim, followed by azathioprine. They
discovered allopurinol, which blocks the formation of uric acid and
is used to treat gout.